Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTRJ1K4)

• DTT Name: Toll-like receptor 7 (TLR7) DTT Info
• Gene Name: TLR7

Molecule-Related Drug & Molecule List

2 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydroxychloroquine	DMSIVND	Chronic renal failure	GB61.Z	Approved	[1]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[2]

20 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ANA773	DMSC8YW	Hepatitis C virus infection	1E51.1	Phase 2a	[3]
Afimetoran	DM3HN3U	Systemic lupus erythematosus	4A40.0	Phase 2	[4]
AZD-8848	DM0M7QW	Allergic rhinitis	CA08.0	Phase 2	[5]
GS-9620	DMG5C8D	Hepatitis B virus infection	1E51.0	Phase 2	[6]
GSK2245035	DMBWPZJ	Asthma	CA23	Phase 2	[7]
IMO-3100	DMM549D	Psoriasis vulgaris	EA90	Phase 2	[8]
Isatoribine	DMHOJ8W	Hepatitis C virus infection	1E51.1	Phase 2	[9]
LOXORIBINE	DMIV9ZE	Immune System disease	4A01-4B41	Phase 2	[10]
PF-4878691	DM24I0N	Melanoma	2C30	Phase 2	[11]
Resiquimod	DML6XSP	Actinic keratosis	EK90.0	Phase 2	[12]
BNT411	DMGF2PU	Small-cell lung cancer	2C25.Y	Phase 1/2	[13]
DSP-0509	DM7WK6N	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[14]
NKTR-262	DMYR8LF	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[15]
CPG 52364	DMVDYTG	Systemic lupus erythematosus	4A40.0	Phase 1	[16]
CV8102	DMYD37G	Melanoma	2C30	Phase 1	[17]
DV-1179	DMDSVRP	Autoimmune disease	4A40-4A45	Phase 1	[18]
LHC165	DMYK52O	Solid tumour/cancer	2A00-2F9Z	Phase 1	[19]
MEDI9197	DM0J7UR	Solid tumour/cancer	2A00-2F9Z	Phase 1	[20]
RG6115	DM6TLPD	Hepatocellular carcinoma	2C12.02	Phase 1	[21]
RG7854	DMGLXQ9	Hepatitis B virus infection	1E51.0	Phase 1	[21]

3 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IM0-8400	DMEF9JW	Diffuse large B-cell lymphoma	2A81	Discontinued in Phase 1/2	[22]
ANA-975	DMFR3PD	Immune System disease	4A01-4B41	Discontinued in Phase 1	[9]
IPH-3201	DM7J8IO	Solid tumour/cancer	2A00-2F9Z	Terminated	[23]

3 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TMX-201	DMULO0V	Autoimmune diabetes	5A10	Investigative	[23]
TMX-202	DMPX3WT	Bladder cancer	2C94	Investigative	[23]
TMX-30X	DMSEAMU	Autoimmune diabetes	5A10	Investigative	[23]

References

• [1] TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets. 2007 Dec;6(4):223-35.
• [2] Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J Invest Dermatol. 2009 Nov;129(11):2676-85.
• [3] Clinical pipeline report, company report or official report of Anadys Pharmaceuticals (2011).
• [4] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [5] Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis. Respir Res. 2012 Jun 22;13:53.
• [6] Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses. J Pharmacol Exp Ther. 2014 Jan;348(1):96-105.
• [7] Early clinical evaluation of the intranasal TLR7 agonist GSK2245035: Use of translational biomarkers to guide dosing and confirm target engagement. Clin Pharmacol Ther. 2015 Oct;98(4):369-80.
• [8] Company report (Iderapharma)
• [9] Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine. Nucleosides Nucleotides Nucleic Acids. 2007;26(6-7):635-40.
• [10] The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol. 2003 Nov;33(11):2987-97.
• [11] The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691). Clin Pharmacol Ther. 2011 Jun;89(6):821-9.
• [12] TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).Vaccine.2005 Nov 1;23(45):5263-70.
• [13] Clinical pipeline report, company report or official report of BioNTech.
• [14] Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
• [15] Clinical pipeline report, company report or official report of Nektar Therapeutics.
• [16] Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus. Lupus Foundation of America, Inc. 2007.
• [17] Clinical pipeline report, company report or official report of CureVac.
• [18] Company report (Dynavax)
• [19] Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes. Eur J Med Chem. 2020 May 1;193:112238.
• [20] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [21] Clinical pipeline report, company report or official report of Roche.
• [22] Clinical pipeline report, company report or official report of Idera Pharmaceuticals.
• [23] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1757).